CN102702359A - 新的IgE表位的鉴别 - Google Patents

新的IgE表位的鉴别 Download PDF

Info

Publication number
CN102702359A
CN102702359A CN2011103434066A CN201110343406A CN102702359A CN 102702359 A CN102702359 A CN 102702359A CN 2011103434066 A CN2011103434066 A CN 2011103434066A CN 201110343406 A CN201110343406 A CN 201110343406A CN 102702359 A CN102702359 A CN 102702359A
Authority
CN
China
Prior art keywords
antibody
leu
ige
arg
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011103434066A
Other languages
English (en)
Chinese (zh)
Inventor
桑贾亚·辛格
黄丹阳
锡·钟·迈克尔·冯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/002894 external-priority patent/WO2004070011A2/en
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of CN102702359A publication Critical patent/CN102702359A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011103434066A 2004-02-02 2004-07-29 新的IgE表位的鉴别 Pending CN102702359A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USPCT/US04/02894 2004-02-02
PCT/US2004/002894 WO2004070011A2 (en) 2003-02-01 2004-02-02 HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
USPCT/US04/02892 2004-02-02
PCT/US2004/002892 WO2004070010A2 (en) 2003-02-01 2004-02-02 A method for generating high affinity antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200480041292.8A Division CN1926149A (zh) 2004-02-02 2004-07-29 新的IgE表位的鉴别

Publications (1)

Publication Number Publication Date
CN102702359A true CN102702359A (zh) 2012-10-03

Family

ID=34841291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011103434066A Pending CN102702359A (zh) 2004-02-02 2004-07-29 新的IgE表位的鉴别

Country Status (8)

Country Link
EP (1) EP1718669A4 (ko)
JP (1) JP2008507474A (ko)
KR (4) KR101365375B1 (ko)
CN (1) CN102702359A (ko)
AU (2) AU2004315197B2 (ko)
CA (1) CA2552999A1 (ko)
SG (2) SG149892A1 (ko)
WO (1) WO2005075504A1 (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2056849A4 (en) * 2006-08-04 2010-09-08 Univ Pennsylvania METHODS AND COMPOSITIONS FOR TREATING IGE MEDIATED DISEASES
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2677597A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
JP2011507816A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP3565587A4 (en) * 2017-01-06 2020-12-16 The Regents of The University of California THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS
KR20200135826A (ko) * 2018-03-26 2020-12-03 노파르티스 아게 리게리주맙을 사용하여 만성 자발성 두드러기를 치료하는 방법
EP4355362A1 (en) 2021-06-14 2024-04-24 Novartis AG Pharmaceutical formulation containing an anti-ige antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229021A1 (en) * 1998-04-09 2003-12-11 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1452542A3 (en) * 1992-09-24 2007-05-02 Novartis AG Reshaped human monoclonal antibodies specific for IgE
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
DE69922873T2 (de) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Spezifische Bindungsproteine zur Behandlung von Allergien beim Hund
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
HUP0105490A3 (en) * 1999-02-25 2002-05-28 Peptide Therapeutics Ltd Cambr Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
GB0020717D0 (en) * 2000-08-22 2000-10-11 Smithkline Beecham Biolog Novel compounds and process
EP1967205B1 (en) * 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
WO2004070010A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229021A1 (en) * 1998-04-09 2003-12-11 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor

Also Published As

Publication number Publication date
SG183683A1 (en) 2012-09-27
KR101365375B1 (ko) 2014-02-19
SG149892A1 (en) 2009-02-27
KR101581659B1 (ko) 2015-12-31
JP2008507474A (ja) 2008-03-13
KR20140021058A (ko) 2014-02-19
AU2009202408A1 (en) 2009-07-09
KR101562114B1 (ko) 2015-11-20
EP1718669A1 (en) 2006-11-08
CA2552999A1 (en) 2005-08-18
KR20130088198A (ko) 2013-08-07
EP1718669A4 (en) 2007-10-10
AU2004315197B2 (en) 2009-06-04
AU2004315197A1 (en) 2005-08-18
KR20120056297A (ko) 2012-06-01
KR20070008578A (ko) 2007-01-17
WO2005075504A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
CN1771338B (zh) 高亲和力抗人类IgE抗体
CN101563366A (zh) 抗notch3激动性抗体及其在治疗notch3相关疾病中的用途
AU2009202408A1 (en) Identification of novel IgE epitopes
US20110200604A1 (en) IDENTIFICATION OF NOVEL IgE EPITOPES
US6639057B1 (en) Monoclonal antibody against human telomerase catalytic subunit
CN106749645B (zh) 一种全人源抗丙型肝炎病毒的中和抗体
KR102663963B1 (ko) 코로나-19 바이러스 표적 인간 항체
WO2022068895A1 (zh) 抗SARS-CoV-2刺突蛋白膜外区的单克隆抗体及其应用
KR20220143255A (ko) 코로나-19 바이러스 표적 인간 항체
MXPA06008690A (es) Identificacion de epitopos ige novedosos
KR20210128252A (ko) 코로나-19 바이러스 표적 인간 항체
AU2012261739A1 (en) Identification of novel IgE epitopes
CN1926149A (zh) 新的IgE表位的鉴别

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121003